Singapore markets closed
  • Straits Times Index

    -22.61 (-0.73%)
  • S&P 500

    -12.37 (-0.28%)
  • Dow

    +71.37 (+0.21%)
  • Nasdaq

    -77.73 (-0.52%)

    -1,367.92 (-3.14%)
  • CMC Crypto 200

    -59.14 (-5.37%)
  • FTSE 100

    -3.85 (-0.05%)
  • Gold

    -17.20 (-0.98%)
  • Crude Oil

    +0.40 (+0.53%)
  • 10-Yr Bond

    +0.0530 (+3.57%)
  • Nikkei

    -56.10 (-0.19%)
  • Hang Seng

    +291.61 (+1.20%)
  • FTSE Bursa Malaysia

    +13.77 (+0.90%)
  • Jakarta Composite Index

    -9.38 (-0.15%)
  • PSE Index

    -70.90 (-1.02%)

Cystic Fibrosis Drug Pipeline Research Report 2021 -

·4-min read

DUBLIN, August 05, 2021--(BUSINESS WIRE)--The "Cystic Fibrosis - Pipeline Insight, 2021" clinical trials has been added to's offering.

This Cystic Fibrosis - Pipeline Insight, 2021 provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Cystic Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cystic Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Cystic Fibrosis.

Cystic Fibrosis Emerging Drugs Chapters

This segment of the Cystic Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cystic Fibrosis Emerging Drugs

ELX-02: Eloxx Pharmaceuticals

ELX-02, is a eukaryotic ribosomal selective glycoside (ERSG) designed to increase the read-through activity in patients with nonsense mutations and enable the production of sufficient amounts of full-length functional protein to restore activity. It is currently in phase II stage of development to treat Cystic fibrosis.

NM002: NovaBiotics

NM002 is an immunomodulator-antimicrobial (antiviral and antibacterial) and NovaBiotics' data suggest that its multi-active properties could provide significant benefit in the treatment of CAP. The active pharmaceutical ingredient of NM002, cysteamine, is an endogenous innate immune effector with an underappreciated role in the treatment of the inflammatory consequences of infection.

Cystic Fibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cystic Fibrosis

There are approx. 60+ key companies which are developing the therapies for Cystic Fibrosis. The companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. phase II include, Eloxx Pharmaceuticals.


This report covers around 60+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • intravenous

  • Subcutaneous

  • Topical.

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cystic Fibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystic Fibrosis drugs.

Cystic Fibrosis Report Insights

  • Cystic Fibrosis Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Cystic Fibrosis Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cystic Fibrosis drugs?

  • How many Cystic Fibrosis drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystic Fibrosis?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cystic Fibrosis therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Cystic Fibrosis and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Eloxx Pharmaceuticals

  • NovaBiotics

  • Arrowhead Pharmaceuticals

  • SolAeroMed

  • Parion Sciences

  • Translate Bio, Inc.

  • Path BioAnalytics

  • Aridis Pharmaceuticals

  • Novartis

  • Vertex Pharmaceuticals

  • AlgiPharma

  • Proteostasis Therapeutics, Inc.

  • Corbus Pharmaceuticals

  • Galapagos NV

  • Santhera Pharmaceuticals

  • Calithera Biosciences, Inc

  • AbbVie

  • Spyryx Biosciences, Inc.

  • Verona Pharma

  • Laurent Pharmaceuticals Inc.

  • Ionis Pharmaceuticals, Inc.

  • Chiesi Farmaceutici S.p.A.

  • Ligand Pharmaceuticals

  • Boehringer Ingelheim

  • OrPro Therapeutics

  • Protalix Biotherapeutics

  • Laurent Pharmaceuticals

Key Products

  • ELX-02

  • NM002

  • ARO ENaC

  • S-1226

  • P-1037

  • MRT5005

  • Cavosonstat

  • AR-501

  • QBW276

  • VX-121

  • OligoG

  • PTI-808

  • JBT-101

  • GLPG1837

  • POL6014

  • CB-280

  • Galicaftor

  • SPX-101

  • RPL554

  • LAU-7b


  • CHF 6333

  • Theradux

  • PRX 110

  • LAU-7b

For more information about this clinical trials report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting